Travere Therapeutics (TVTX) Other Non-Current Assets (2013 - 2026)

Travere Therapeutics' Other Non-Current Assets history runs 14 years deep, the most recent figure standing at $8.5 million for Q1 2026.

• Quarterly Other Non-Current Assets fell 54.65% year-over-year to $8.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.5 million (down 54.65% YoY) and the FY2025 annual result came in at $8.9 million, down 51.11% from the prior year.
• Other Non-Current Assets was $8.5 million for Q1 2026 at Travere Therapeutics, down from $8.9 million in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $19.6 million in Q2 2025 and bottomed at $3.0 million in Q4 2022.
• A 5-year average of $12.9 million and a median of $11.1 million in 2022 frame the typical range for Other Non-Current Assets.
• Annual changes were most pronounced in 2022 — Other Non-Current Assets slumped 72.99% — and 2023, when it soared 256.56%.
• Travere Therapeutics' Other Non-Current Assets stood at $3.0 million in 2022, then surged by 256.56% to $10.7 million in 2023, then surged by 70.36% to $18.2 million in 2024, then tumbled by 51.11% to $8.9 million in 2025, then fell by 4.55% to $8.5 million in 2026.
• Business Quant data shows TVTX's Other Non-Current Assets at $8.5 million in Q1 2026, $8.9 million in Q4 2025, and $10.3 million in Q3 2025.